"Subtotal Percutaneous Cryoablation for Extra-Abdominal Desmoid Tumors" with Joseph G. Pressey, MD
With Dr. Joseph G. Pressey
Chapter 3 of 5
Cohort outcomes
Patient cohort characteristics and outcomes
Cued at 4:15 · press play
Expert statements on this page
No expert statements were drawn from this page.
Host summaries · secondary, not cited in answers
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
What the experts said
At Cincinnati Children's Hospital, gamma secretase inhibitors are considered standard of care for patients requiring medical therapy, especially young adults and older adolescent pediatric patients.
Cryoablation is an interventional radiology ablative procedure that uses argon gas to create an ice ball.
One to three probes are typically used for cryoablation depending on the size and shape of the tumor.
The tumor is frozen down to minus 140 to minus 190 degrees Fahrenheit during cryoablation, forming an ice ball around part or all of the tumor.
Cincinnati Children's Hospital has been offering cryoablation for desmoid tumors since 2021.
Cincinnati Children's uses a standard two-cycle freeze-thaw approach to cryoablation.
Nerve monitoring is performed when vital nerves run near the tumor, and skin warming is used to prevent necrosis of overlying skin.
Patients are under general anesthesia during cryoablation and typically admitted to the hospital afterwards for pain control, usually overnight but up to three days depending on location and treatment plan.
Cryoablation procedures are often ultrasound or CT guided.
Cincinnati Children's has treated 14 patients with 25 technically successful cryoablation procedures for desmoid tumors.
The patient cohort ranged from 8 to 43 years of age with a median age of 20 years.
Patients required one to three probes during therapy and had anywhere from one to four procedures depending on tumor size and shape.
Some tumors got larger after cryoablation while others dramatically shrunk in size.
Tumors that decreased in size also showed decreased T2 hyperintensity on MRI.
At 12 months after cryoablation, 86% of patients had not started a new medical therapy.
At 36 months after cryoablation, 55% of patients had not started a new medical therapy.
The patient cohort was heterogeneous and many had been heavily pre-treated.
Pazopanib is very much like sorafenib, cousins in effect.
Nine out of 13 patients reported improved pain after cryoablation.
Six out of 11 patients reported improved function after cryoablation.
There were no grade 3 or grade 4 toxicities from cryoablation in this cohort.
Cincinnati Children's has taken a modest approach where 30 to 90% of the tumor is frozen, not attempting to freeze the entire tumor unless very easy to do.
Subtotal cryoablation was found to be effective and safe.
Approximately half of the patients did not require subsequent new medical therapy after undergoing cryoablation.
Many patients had received medical therapy up until the point where they underwent cryoablation.
There appear to be no overlapping toxicities between prior medical therapy and subsequent cryoablation.
Nirogastat and presumably other gamma secretase inhibitors work well for desmoid tumors based on published DeFi study data.